# Cost-effectiveness of geographically targeted versus ring vaccination campaigns in response to an outbreak of Ebola Virus Disease

Gemma Nedjati-Gilani[1], Carl A. B. Pearson[2], Janetta E. Skarp[1], Wes Hinsley[1], Steven Riley[1],
Abigail Hunter[1], Neil M. Ferguson[1,3], Katharina D. Hauck[1,3], and Anne Cori[1]

[1]MRC Centre for Global Infectious Disease Analytics, Imperial College London, London, UK

[2]Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA

[3]Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London,
London, UK

May 2025

**Abstract**

For response to an outbreak of Ebola Virus Disease (EVD), the World Health Organisation (WHO) guidelines recommend vaccination of any contacts and contacts-of-contacts of identified EVD cases, also known as ring vaccination. However this standard response can be challenging to implement in remote regions or conflict zones. In recent outbreaks, response efforts have also tried blanket vaccination in the immediate vicinity of the homes and workplaces of identified cases, also known as geographically targeted vaccination. The relative effectiveness of these deployment strategies is difficult to study empirically, and modelling work to date has been limited.

In this study, we use a spatially explicit individual-based stochastic simulation to model an EVD epidemic and public health response using either ring or geographically targeted vaccination alongside standard response activities. We explore a wide range of outbreak scenarios and response levels.

Overall, we find little difference between ring or geographically targeted vaccination for either health or cost outcomes; the quality of surveillance and effectiveness of standard response activities are much larger drivers. However, vaccination does provide incremental benefit in combination with those activities, and the preferred strategy changes depending how well non-pharmaceutical activities are executed. Ring vaccination provides more incremental benefit on top of otherwise effective response activities (e.g. rapid and high ascertainment of contacts) but geographically targeted vaccination is better when those activities are less effectively delivered.

These findings are relevant to policy makers deciding how to most effectively and cost-effectively deploy EVD vaccines in resource-limited and often challenging outbreak settings.

# 1 Introduction

Since the Ebola Virus (EBOV) was first isolated in Sub-Saharan Africa in 1976 [1], there have been ongoing efforts to develop a vaccine [2]. However, early development work was limited by the sporadic nature and limited size and duration of subsequent Ebola Virus Disease (EVD) outbreaks. Unpredictability in both the timing and location of outbreaks and their small scale limited the feasibility of carrying out necessary efficacy trials. This changed in 2014 with the West African EVD epidemic. The epidemic, which lasted until 2016, remains the largest EVD outbreak ever recorded, resulting in over 22,000 reported cases and 11,000 deaths, primarily in the West African nations of Guinea, Liberia and Sierra Leone [3]. Manufacturers of several candidate vaccines accelerated development, conducting immunogenicity and safety studies simultaneously, with the aim of carrying out Phase III trials during the ongoing outbreak. By the time trials were ready to start, case numbers in all three affected countries were declining and only the Ebola Ça Suffit trial of the rVSV-Zebov vaccine in Guinea, a cluster randomised ring trial, remained sufficiently powered, estimating a vaccine efficacy (against symptomatic disease) of 100% (95% confidence interval: 79.3-100%) [4], although effectiveness in a real-world outbreak setting has subsequently been revised down to 84% (95% credible interval: 70-92%) [5].

Following the trial, WHO designated ring vaccination as the recommended strategy for EVD outbreaks [6] and regulators granted a compassionate use license for the vaccine in response to future epidemics [7], targeting susceptible contacts and contacts of contacts of known cases [4, 8] using specially trained vaccinators. The vaccine was delivered via ring vaccinations during the 2018-2020 EVD outbreak in Nord Kivu and Ituri provinces in the Democratic Republic of Congo (DRC). However, frequent security concerns and conflict events [9] hampered contact tracing and vaccination teams as they worked to find susceptible contacts and establish vaccination rings [10]. Faced with these difficulties, the vaccination strategy was adapted to include geographically targeted vaccination [8], which allowed individuals living in proximity to a diagnosed case to attend ad hoc vaccination clinics, regardless of whether they had been in direct contact.

The experience demonstrated that the added value of ring vaccination is highly dependent on contact tracing performance. When contact tracing is highly effective, outbreaks can be controlled by quickly tracking contacts of cases and isolating them if they develop symptoms, making vaccination potentially unnecessary; when contact tracing is ineffective and a large proportion of contacts are not found, ring vaccination fails to find and protect those most vulnerable to infection, thus failing to break chains of transmission.

This raises important questions regarding the relative effectiveness and cost-effectiveness of the two alternative strategies of ring vaccination versus geographical targetting, in which situations each should be deployed, and the vaccine stockpile size necessary to deploy them.

A number of epidemiological modelling studies have been published examining the benefits of vaccination campaigns during EVD outbreaks. However, most of these studies focus on a single vaccination strategy, such as healthcare worker (HCW) vaccination [11, 12, 13], mass vaccination [14] or ring vaccination [15, 16, 17]. Models that do consider more than one vaccination strategy tend to focus on combined strategies [18, 19], or comparing preventative versus reactive vaccination [20] rather than directly comparing the relative impact of different reactive vaccination strategies.

From the economic perspective, several studies have attempted to determine cost-effectiveness thresholds [21, 22] and price points [23] for EVD vaccination programmes. However, the epidemiological models used by those

studies were simple deterministic models that cannot represent the complex spatial and stochastic features of Ebola outbreaks, the complexities of different vaccine delivery strategies, or targeted response activities such as contact tracing. As such, it is unlikely that these models accurately capture the dynamics of outbreaks, and therefore the benefits and costs of vaccination strategies. The comparative costs and cost-effectiveness of ring- versus geographically targeted vaccination campaigns have never been analysed.

In this study, we use a spatially explicit individual-based stochastic simulation model to compare the cost-effectiveness of rolling out ring and geographically targeted vaccination campaigns against EVD, using DRC, the country which has recorded the most outbreaks, as an exemplar case. We consider a range of plausible transmission scenarios, times to outbreak detection and response levels (including contact tracing, case ascertainment, vaccination, safe burials and Ebola treatment centres). We then compare the effectiveness and cost effectiveness of the proposed geographically targeted strategy with the current gold standard of ring vaccination, under two assumptions: first that the two vaccination strategies have similar acceptability and efficacy, and second assuming that geographically targeted vaccination can be deployed more effectively than ring vaccination, which is highly stigmatised [24]. This work is necessary to provide governments and policy makers with much needed evidence on how to effectively respond to EVD outbreaks and deploy costly vaccines in the most cost-effective way.

## 2  Methods

In this section, we provide an overview of the individual-based model used to simulate EVD outbreaks, the model parameters, and the range of scenarios we explore in this work. The model first constructs a demographically realistic synthetic population and then simulates an EVD epidemic, and associated response measures, within that population. We provide a brief description of the three components of the model below.

The results in this paper were generated using our *ebolasim* microsimulation code, written in C. This model extends the individual-based influenza stochastic simulation model by Ferguson et al [25], adding features to enable modelling specific aspects of EBOV transmission dynamics and associated outbreak response to EVD epidemics. In particular, the model includes a period of postmortem infectiousness as well as safe and dignified burials, contact tracing, specialised Ebola treatment centres and vaccination; further details are provided in the section below on the response activity model.

### 2.1  Synthetic population

We consider an outbreak of EVD in North-East DRC focusing on Nord Kivu, Ituri, Haut-Uele, Tshopo, Maniema and South Kivu provinces (admin 1 unit), an area with a total population of 22,323,000 people. In modelling transmission and interventions, the simulation makes use of administrative level 2 geographic units, termed territories in DRC. Thus, the simulation models the outbreak in 39 territories across 6 provinces. The simulation area is divided into a grid of $1/120$ degree cells (approximately $1\mathrm{km}^2$) and the population size of each cell is assigned according to the Landscan 2018 population database [26]. Administrative boundaries are designated using Global Administrative Areas (GADM) data [27]. Individuals are assigned ages and are grouped into households based on household size distributions informed by the 2013-2014 Demographic and Health Surveys (DHS) data [28]. We model extended family networks by subdividing household members into groups and connecting them with similar groups from other nearby households. These networks are then used to generate the list of contacts and contacts

of contacts used during ring vaccination. The network size distribution is informed by data published on the mean number of people per vaccination ring during the 2018-2020 EVD outbreak [8]. Full details are presented in the Supplementary Information.

## 2.2 Transmission model

After the simulated population has been initialised, we seed the infection of one individual in Nord Kivu, chosen randomly for each realisation. The infected individual's incubation period is sampled from a gamma distribution parameterised using data from the 2014-2016 West African outbreak [29]. Following the end of the incubation period, the individual becomes infectious and on the next time step develops symptoms. For infected individuals, we also sample the duration of infectiousness based on data from the 2014-2016 West Africa epidemic [29]. We then calculate the relative probability of death versus recovery for that infectious duration and use that probability to draw the individual's outcome. The individual's infectiousness is sampled from a gamma distribution with mean 1 and standard deviation 2, which was matched to data from West Africa in order to capture potential super-spreading events [30]. This infectiousness remains constant until the individual recovers or dies. At each time step in the infectious period, individuals may infect members of their household, extended family network or wider community, dependent on their household, extended family network, and community force of infection as illustrated in figure 1 and detailed in [25] and the Supplementary Information. Individuals who die then have a period of enhanced infectiousness for one day after death to capture increased transmission at funerals. Postmortem infectiousness is calibrated to the number of funeral infection events during the 2014-2016 West African outbreak [30]. We simulated outbreaks out to a horizon of four years after the initial infection event and used a time step of 0.25 days.

## 2.3 Outbreak response model

### 2.3.1 Outbreak detection and case ascertainment.

In the initial stages of a simulated outbreak, cases can only be detected by routine, passive surveillance. The first detection of an EVD case triggers outbreak response activities. We consider three initial outbreak detection scenarios: early, intermediate, or late. These scenarios are characterized by the number of missed infections occurring prior to the first detection of a case and the outbreak being recognised. Outbreaks that go extinct before being detected, and therefore do not prompt an outbreak response, are not included in the analysis. The number of initial undetected infections can range from tens [31] to hundreds [32, 33]. We denote the time of first detection of a case as time zero for the response, against which delays in rolling out and duration of interventions are measured. Following outbreak detection, a certain proportion of cases are ascertained, depending on whether the outbreak response level matches the worst-case, realistic or best-case. The values used are shown in table 1 and section 2.4.

### 2.3.2 Safe burials.

Safe burial teams are deployed 7 days after outbreak detection [34]. We assume that all fatal hospitalised cases and 80% of fatal non-hospitalised but detected cases are given safe burials [35, 36] and that a safe burial reduces the postmortem infectiousness of the deceased individual by 80% [30].

Figure 1: The map shows the outline of the 39 territories of 6 North Eastern provinces in Democratic Republic of the Congo included in the simulation, colour-coded according to population density. Lighter areas show low population density regions and darker areas show higher population density regions. Around the map, we illustrate how the landscape is divided into cells, how the population is divided into households and extended family networks, and transmission routes. Each cell contains households with exact locations. The number of household members is sampled according to demographic information. In cell 1, an infectious individual (red) infects a household member who is now exposed (yellow). The dotted circle represents an extended family network comprised of a mix of household members from neighbouring households. These households may be in the same or neighbouring cells. The infectious individual also infects an extended family member from different household, shown in yellow. Infectious individuals also infect individuals to whom they do not have a household or family link, as shown in cell 3.

### 2.3.3 Ebola Treatment Centres (ETCs).

Following outbreak detection, an ETC is established in each territory once 5 cases have been detected there. We assume a two-week construction period, after which the ETC becomes operational with a capacity of 12 beds. When the ETC is at 80% capacity, it is earmarked for expansion; after a delay of 7 days, an additional 12 beds become available. This process can be repeated multiple times, dependent on occupancy, and each time the expansion takes 7 days and results in an additional 12 beds. However, a new expansion cannot begin until the previous one has been completed. We assume a fixed delay from case detection to hospitalisation, which is shorter for individuals who are contacts under active investigation. If a bed is available in the ETC of a cases's residential territory, the individual is admitted to that ETC until recovery or death, which reduces their contacts with household, family, and community members by 80%. If no bed is available, the individual remains in the community until they recover or die and their contact rates with household, family and community members are unchanged.

### 2.3.4 Contact tracing.

Contact tracing is activated 2 days after outbreak detection [37], and contact tracing teams are deployed to each territory once a case has been detected there. We assume that each territory has the capacity to follow up 5000 contacts at any given time, based on the maximum reported number of contacts traced per active health zone [38] multiplied by the average number of health zones per territory. When a detected case triggers contact tracing, a proportion of their household members and extended family network are added to a list of contacts to follow for up to 21 days [39]. If the territory is at contact tracing capacity when a case is detected, the contacts of the case are not added to the contact tracing list, even if capacity were to become available later on in the 21-day period following detection of the case. A proportion of contacts being traced are lost to follow-up during the 21-day period, and the day on which they are lost to follow-up is randomly selected. We assume that traced contacts who become cases during their follow-up period are detected on the day of symptom onset.

### 2.3.5 Vaccination.

Vaccination roll-out begins 7 days after the outbreak is detected [37]. We compare the effectiveness of two vaccination strategies: ring and geographically targeted. For both, we assume a delay between ascertaining a case and deploying a vaccination team to respond. We assume a delay of 10 days for vaccinated individuals to be protected by the vaccine [5], during which the vaccine does not provide protection. Following this delay, we assume that the vaccine is 84% effective at protecting against disease [5]. We assume that the vaccine does not reduce the infectiousness or severity of breakthrough cases and that efficacy does not wane over the simulation period.

We assume that vaccination campaigns are limited by resources. At the beginning of the response, vaccination teams can vaccinate a maximum of 500 individuals per day across all affected regions; this is increased to 1000 individuals/day when the average number of cases ascertained exceeds 1 per day over the past seven days on average, and to a maximum of 1500 individuals/day when the average number of cases ascertained per day exceeds 2 per day over the past seven days and then remains at this level for the rest of the simulation. If vaccination demand exceeds capacity, individuals are added to a vaccination 'queue' to be vaccinated on a subsequent day,

and they remain in the queue until they have been vaccinated or become ineligible (due to symptom onset). Individuals are added to the queue according to when they were identified as eligible for vaccination and the queue is processed in order using random tiebreaks where necessary.

Under the ring vaccination strategy, after a case has been ascertained, a ring of contacts and contacts of contacts is established with a certain probability (see table 1). Note that this means that a ring can only be established around a case for which contact tracing has been undertaken. If a ring is established, we assume high vaccine uptake, with 95% of contacts across the two levels of the ring accepting the vaccine, as this matches outbreak data showing high uptake amongst established rings although difficulty establishing rings around some cases [8].

Under the geographically targeted vaccination strategy, we assume that for each ascertained case, a vaccination team is deployed to the case's 1km$^2$ grid cell with 300 doses of vaccine to administer to individuals living close to the case [8]. If multiple cases are ascertained within the same grid cell at the same time step, we multiply the amount of doses/case by the number of ascertained cases, up to a maximum of 900 doses (private communication: Dr Aminata Bagayoko). We then randomly sample households within the grid cell and vaccinate all household members aged 12 months or over [40], based on the vaccine uptake probability associated with the modelled outbreak response and until all doses have been used. We assume that all household members either all accept, or all reject vaccination. If the number of residents in the cell is less than the number of doses available, the vaccination teams start vaccinating households in neighbouring cells. They start in the closest cells and move out to more distant cells until either all doses have been used or up to a maximum distance of 5km from the ascertained case's cell.

## 2.4 Scenarios and parameterisation

We consider 3 transmission levels, 3 outbreak detection times and 5 response scenarios, described below, resulting in a total of 45 scenarios.

**Transmission levels.** We consider three values of the basic reproduction number $R_0$, the number of cases generated by an infected individual in an otherwise completely susceptible population, corresponding to low ($R_0$=1.5), medium ($R_0$=1.8), and high ($R_0$=2.1) levels of transmission. The chosen transmission levels reflect the range of previous estimates of the basic reproduction number for EVD [41].

**Outbreak detection times.** We consider early, medium, and late outbreak detection, corresponding to 20, 40 and 100 undetected infections before the first detection of a case respectively. These values reflect previous estimates of the number of unobserved cases before outbreak detection [32, 31].

**Response scenarios.** We consider 5 response scenarios in total by considering reasonable worst-case, realistic, and reasonable best-case parameter sets for case ascertainment, contact tracing and vaccination. The parameters for each response scenario are presented in table 1 and have been chosen to closely align with the available literature on levels of case ascertainment, contact tracing and vaccination. For 3 scenarios, we assume that the response level for all activities align, e.g. that case ascertainment, contact tracing and vaccination all correspond to the worst-case parameters, and refer to these scenarios as 'worst-case', 'realistic and 'best-case' respectively. However, we note that some communities consider geographically targeted vaccination to be more acceptable than ring vaccination due to the high level of stigma attached to being a contact of a case [24], and that geographically targeted vaccination can be carried out efficiently even when case ascertaining and contact tracing

| Parameters | | Response scenario | | | Ref |
|---|---|---|---|---|---|
| Parameter type | Parameter name | *Worst-case* | *Realistic* | *Best-case* | |
| Case ascertainment | Proportion of ascertained cases who are not traced contacts | 0.33 | 0.61 | 0.83 | [42] |
| | Fixed delay from symptom onset to case ascertainment (days) | 8 | 6 | 3 | [8] |
| Contact tracing | Proportion of contacts traced | 0.74 | 0.85 | 0.96 | Expert consultation |
| | Proportion of contacts lost to follow-up | 0.50 | 0.25 | 0.05 | [43, 35] |
| Vaccination | Fixed delay from symptom onset to vaccination triggered (days) | 10 | 7 | 3.5 | [4] |
| | Probability of establishing a ring for ring vaccination | 0.66 | 0.83 | 1 | [8] |
| | Vaccine uptake for ring vaccination | 0.95 | 0.95 | 0.95 | [8] |
| | Vaccine uptake for geographically targeted vaccination | 0.63 | 0.78 | 0.95 | Expert consultation |

Table 1: Simulation model parameters for worst-case, realistic and best-case outbreak responses

is difficult. Therefore, for the remaining two scenarios, we decouple the effectiveness of geographically targeted vaccination from non-vaccination activities and pair best-case geographic vaccination parameters with worst-case case ascertainment and contact tracing ('worst-case + best geo'), and realistic case ascertainment and contact tracing ('realistic + best geo'), and compare them to the worst-case and realistic-case ring vaccination responses. For ring vaccination, note that the probability of accepting vaccination given the establishment of a ring remains high at 95%. However, when multiplied by the probability of establishing a ring, the overall probability of vaccination is equal to the corresponding probability for geographic vaccination uptake.

## 2.5 Simulations and Outputs

We generate 500 stochastic outbreak simulations for each of the 45 scenarios considered. Simulated outbreaks continue until the outbreak goes extinct or the maximum time limit of 4 years is reached. For each simulated outbreak, the model aggregates and outputs daily numbers of infections, cases, detected cases, deaths, safe burials, vaccine doses used, and contacts traced, as well as outbreak length, conditional on outbreaks being detected.

## 2.6 Health economic analysis

We calculate additional outcomes related to health impacts and costs using a custom post-processing Matlab [44] script. To calculate discounted years of life lost (DYLL), we use the number simulated age-stratified deaths, and assume a life expectancy of 63 years [45]. Discounting of 3% per year is applied to future life years lost [46].

To provide cost estimates for each scenario, we use the cost data collated by Wu et al [47] from the 2018-2020 Nord Kivu outbreak in DRC. We use unit costs where possible; however, we calculate the unit cost per safe burial by dividing the budgeted costs for safe burials [47] by the 22,921 safe burials listed in the situation reports by the

end of the 2018-2020 North Kivu outbreak [48, 49]. We multiply the costs of the rapid response team (per month) by the length of the simulated outbreaks in months, and points of entry/control surveillance (per month) by the length of the simulated outbreaks in months and the number of territories affected, assuming one point of entry per territory. The outbreak length in months is the time from the first ascertained case to the last ascertained case in days, plus 42 days to account for the active observational period following the final case [50], divided by 30 days per month. The outbreak length in months can take fractional values. We multiply the cost of contact tracing and surveillance (per identified case), laboratory tests (per identified case) by the number of simulated detected cases. To calculate the total cost of treatment, we add the cost of a confirmed case in a treatment centre (per treated case) to the cost of a confirmed case in a transit centre (per treated case) and multiply this by the simulated number of hospitalised cases. We multiply the cost of vaccination (per vaccinated individual) by the simulated total number of individuals vaccinated, and the cost of a safe burial by the simulated number of safe burials conducted. We calculate the total cost of the response by summing the costs of all interventions.

To compare the cost-effectiveness of two different vaccination strategies within one of our scenarios, we pair up the realisations from each strategy that were simulated with identical initial random number generator seeds so that the course of the epidemic is identical until the initialisation of the vaccination programmes. We then calculate the incremental net monetary benefit (INMB) of geographic vaccination relative to ring vaccination for each pair of epidemic simulations $i$ within strategy $j$ according to

$$\text{INMB}_i^j = \text{VSLY}_{DRC}(\text{DYLL}_{ring,i}^j - \text{DYLL}_{geo,i}^j) - (\text{C}_{geo,i}^j - \text{C}_{ring,i}^j), \tag{1}$$

where $\text{DYLL}_{geo,i}^j$ and $DYLL_{ring,i}^j$ are the discounted years of lives lost for realisation $i$ and scenario $j$ associated with geographically targeted and ring vaccination respectively, $\text{C}_{geo,i}^j$ and $\text{C}_{ring,i}^j$ are the corresponding outbreak costs, and $\text{VSLY}_{DRC}$ is the statistical value of a life year for DRC. We estimate $\text{VSLY}_{DRC}$ to be 4.5 times the gross national income (GNI) per capita, based on research into the value of a statistical life-year in Sub-Saharan Africa [51]. According to the World Bank, the GNI per capita for Guinea in 2020 was $460 USD [52], resulting in a VSLY of $2070.

Calculating $\text{INMB}_i^j$ for all 500 realisations of each scenario provides us with a distribution of INMBs of geographic vaccination relative to ring vaccination. However, to further understand whether differences in costs or benefits are driving the shape of the INMB distributions, we also calculate the incremental cost effectiveness ratio $\text{ICER}_i^j$, i.e. the difference in benefits divided by the difference in costs for all realisations of a given scenario, and plot these on ICER planes.

# 3    Results

We present results for the moderate transmission level ($R_0$=1.8), which is our central scenario. Sensitivity analyses showing results for low and high transmission levels are presented in the Supplementary Information.

**Epidemiological impact**   The swarm plots in figure 2 compare the distributions of cases (panel A), deaths (panel B), and epidemic length (panel C) across for worst-case, realistic and best-case response scenarios for both geographic and ring vaccination strategies. Overall, there is no significant difference between geographic and ring vaccination for any of the outcomes or scenarios considered here. However, general trends emerge regarding how

Figure 2: Swarm plots showing A: number of cases, B: number of deaths, and C: epidemic length (in days) for worst-case (left), realistic (centre) and best-case (right) outbreak responses (see table 1) when employing ring (blue) and geographically targeted (red) vaccination strategies, and for early, medium and late response times (indicated by transparency levels). Each point represents a single simulated outbreak. Results are for the moderate transmission level scenario. Note that panels A and B are shown on a log scale whereas panel C is on a linear scale. The mean of each distribution is marked with a black, horizontal line.

response level and outbreak detection time influence which vaccination strategy has more impact.

We find that ring vaccination is slightly preferable to geographically targeted vaccination with respect to all outcomes for the realistic or best-case outbreak response scenarios. In these scenarios, choosing ring over geographic vaccination results in slightly fewer cases and deaths, and slightly shorter epidemics. For example, assuming a realistic response and medium outbreak detection time, the mean number of cases using a geographic strategy is 256 (standard error on the mean SEM=12) compared to 210 (SEM=8) when using ring vaccination, a difference of 46 cases. When the outbreak is detected late, the mean case numbers rise to 520 (SEM=15) and 415 (SEM=10) for geographic and ring vaccination respectively, a difference of 105. The tails of the case number distributions also narrow slightly when using ring vaccination as opposed to geographically targeted vaccination. The 95th percentiles of outbreak size for ring and geographically targeted vaccination respectively are 468 and 660 for a medium detection time, and 740 and 1041 for a late detection time.

The same pattern is observed for deaths and epidemic length. For a realistic response and medium outbreak detection time, the mean number of deaths when using a geographically targeted vaccination strategy is 192 (SEM=9) compared to 156 (SEM=6) for ring vaccination, and when the outbreak is detected later, these values increase to 390 (SEM=11) and 313 (SEM=8). The respective 95th percentiles of the death distributions are 486 and 350 for medium outbreak detection, and 786 and 548 for late outbreak detection. Outbreaks where ring vaccination is used also tend to be slightly shorter than those that use geographically targeted vaccination; the difference in mean outbreak length is approximately one month, regardless of outbreak detection time.

For the worst-case response scenario, we see the opposite trend: geographically targeted vaccination tends to perform slightly better than ring vaccination. Figure 2 shows that in these scenarios, there is much greater variability in outbreak size and duration. When detected early, some simulated outbreaks are self-limiting and quickly go extinct, while others grow very large, reaching tens of thousands of cases. However, when the outbreak is detected late, all outbreaks have at least 100 cases, which is more than most recorded outbreaks, and the biggest outbreaks cause hundreds of thousands of cases. These large outbreaks tend to continue past the end of the four year simulation period. Such simulations may be unrealistic; in a real epidemic situation, it is likely that an initially worst-case response will be bolstered as case numbers rise, as observed during the West African EVD outbreak. However, in the event of a sustained worst-case response, the case and death distributions now have longer tails under ring vaccination than geographically targeted vaccination, indicating that when case ascertainment and contact tracing rates are low, geographically targeted vaccination is likely to curb the largest outbreaks more often.

We observe similar patterns for low transmission scenarios, although the differences between vaccination strategies is minimal, particularly when the outbreak is detected early (figure S4), and only become apparent as the time to outbreak detection increases. The patterns are also similar for high transmission simulations with realistic and best-case outbreak response scenarios. However, when run with the worst-case outbreak response, high transmission simulations generate catastrophic epidemics for all outbreak detection times and both vaccination strategies (figure S5), resulting in millions of cases and deaths over multiple years. These catastrophic outcomes are most likely due to ineffective controls and resource constraints; geographically targeted vaccination uses from 300 up to a maximum of 900 doses per square kilometre per vaccination event, and both vaccination strategies are limited to a maximum of 1500 doses administered per day, values based on field experience from past outbreaks. These constraints lead to long vaccination queues and drawn-out epidemics, with vaccination

| Detection time | Summary statistic | Worst-case | | Realistic | | Best-case | |
|---|---|---|---|---|---|---|---|
| | | Ring | Geo | Ring | Geo | Ring | Geo |
| Early | Mean | 109,500 | 87,700 | 15,100 | 23,600 | 11,200 | 15,700 |
| | 50th | 30,400 | 43,200 | 10,100 | 16,600 | 8,200 | 12,200 |
| | 95th | 523,800 | 298,300 | 47,300 | 72,600 | 29,000 | 42,000 |
| Medium | Mean | 143,600 | 113,100 | 22,400 | 30,200 | 17,000 | 22,300 |
| | 50th | 66,700 | 63,300 | 17,800 | 23,600 | 14,000 | 19,000 |
| | 95th | 579,900 | 378,800 | 57,400 | 91,400 | 39,500 | 52,500 |
| Late | Mean | 235,400 | 196,800 | 42,500 | 53,400 | 32,600 | 39,500 |
| | 50th | 175,400 | 165,600 | 38,500 | 51,000 | 28,900 | 38,800 |
| | 95th | 676,200 | 477,300 | 87,400 | 109,500 | 60,900 | 70,700 |

Table 2: Mean, 50th and 95th percentiles of the number of vaccine doses administered for ring and geographic vaccination strategies, for worst-case, realistic and best-case response levels, and early, medium and late outbreak detection times, rounded to the nearest 100 doses. Shaded cells indicate which vaccination strategy using the fewest doses for the given scenario and summary statistic.

teams facing large backlogs, meaning they are unable to deal with new hot spots. There are simply not enough vaccinations administered or cases ascertained to reduce the effective reproduction number below 1 and thus control the outbreaks.

Importantly, while vaccination strategy does influence case and death distributions, response level and detection time have a much greater impact. Consider the scenario of a realistic outbreak response with a medium detection time and a geographically targeted vaccination strategy. Switching to ring vaccination reduces the mean numbers of cases from 256 (SEM=12) to 210 (SEM=8). In comparison, switching to the best-case response scenario reduced the mean number of cases to 166 (SEM=5), and detecting the outbreak earlier lowers the mean number of cases to 188 (SEM=9).

**Vaccine stockpile needs**  The numbers of vaccine doses used in an outbreak reflects the patterns observed in the case and death distributions (see table 2). Ring vaccination uses fewer vaccine doses than geographically targeted vaccination under realistic or best-case responses, but more doses for the worst-case response scenario. The differences in dose numbers between the two vaccination strategies are large but may be partly driven by resource constraints. For the geographically targeted strategies, the model limits the number of doses that are deployed to vaccinate individuals in an affected area, whereas every detected case can trigger ring vaccination. However, the limit on the number of doses administered daily is common to both ring and geographic vaccination.

To assess the required vaccine stockpile size, we use the 95th percentile of the distribution of doses used in our simulations as a proxy, considering that decision makers are likely to plan enough doses to respond to large, costly outbreaks. Realistic and best-case response scenarios required 110,000 doses or fewer, and this stockpile size is appropriate regardless of vaccination strategy. If the response is worst-case, potentially due to resource limitations or security concerns, the stockpile needed is much larger: almost 500,000 doses for a geographically targeted vaccination strategy, and close to 700,000 doses for a ring vaccination strategy.

We see similar trends for the lower and higher transmission levels (tables S8,S12), although for low transmission simulations, ring vaccination requires fewer doses even in the worst-case response scenario. For the low transmission level, a stockpile of 61,000 doses is sufficient when using ring vaccination, and a stockpile of 67,000 doses is sufficient for geographically targeted vaccination. For high transmission simulations, 280,000 is sufficient for both ring and geographically targeted campaigns, as long as the response is realistic or better, regardless of detection time. However, for the worst-case response, 1.5 million doses are needed for ring vaccination, and

Figure 3: Histograms showing INMB for geographically targeted vaccination relative to ring vaccination. Detection time varies across the rows (top: early, middle: medium, bottom: late) and response level increases across the columns from left to right. Positive values of INMB (in red) indicate that geographically targeted vaccination is more cost effective than ring vaccination, and negative values (in blue) indicate that ring vaccination is more cost effective. In each subplot, the mean INMB for the given scenario is shown, along with the SEM in brackets, and the percentage of positive and negative INMBs.

690,000 doses are needed for geographically targeted vaccination, although this is probably an underestimate due to the simulation run time and geographic constraints.

**Cost effectiveness** Figure 3 shows the distribution of INMBs for geographically targeted compared with ring vaccination. The INMB distributions are broad and approximately centred at zero, making it hard to draw clear-cut conclusions as to which strategy performs best on the level of an individual outbreak. This is largely due to the stochastic nature of the individual-based simulation, which can sometimes result in diverging epidemic trajectories and outcomes as the different strategies are deployed. Similar trends and uncertainty are observed when considering low and high transmission settings (see figures S6 and S10).

When the response is realistic or best-case, ring vaccination outperforms geographically targeted vaccination slightly more often, as indicated by the greater proportion of negative INMBs, and this pattern becomes stronger as time to outbreak detection increases (58% for early detection, 70% for late detection). However, for a worst-case response, we see the opposite trend, with geographically targeted vaccination outperforming ring vaccination (53% and 56% for early and late detection, respectively).

To delve deeper into potential drivers, we plot ICER planes in figure 4. There is a strong negative correlation

Figure 4: ICER planes for geographically targeted vaccination relative to ring vaccination. Detection time varies across the rows (top: early, middle: medium, bottom: late) and response level increases across the columns from left to right. Each point represents a simulation pair. Points in the bottom right corner indicate that geographic vaccination dominates ring vaccination; points in the top left corner indicate that ring vaccination dominates geographic vaccination. Red points show that the simulated epidemic using geographic vaccination is shorter than the matching simulation using ring vaccination. Blue points indicate that the simulated epidemic using ring vaccination is shorter than the matched simulation using geographic vaccination. The dashed line indicates the willingness to pay threshold, i.e. the VSLY.

between incremental benefits and incremental costs: the more beneficial strategies in terms of DYLL averted are also the less costly strategies, and vice versa. This is why most of the ICERs fall in the two quadrants of strong dominance (top left for ring vaccination, bottom right for geographically targeted vaccination). The negative correlation between benefits and costs is likely related to a third factor that has a strong impact on both: outbreak duration. Ring vaccination dominates when it shortens the (matched) outbreaks more than geographically targeted vaccination (blue points), and vice-versa (red points). The strategy that minimises outbreak duration usually results in fewer cases and deaths, and thus DYLLs, and also has lower costs associated with expensive outbreak response activities.

We see similar, albeit weaker, patterns for the low transmission level scenarios (figure S6 and S7) and for high transmission level scenarios with realistic or best-case outbreak responses (figure S10 and S11). For high transmission settings coupled with worst-case response scenarios, the catastrophic outbreaks result in difficult-to-interpret INMBs and ICERs, which are likely impacted by the truncated run time of the simulations.

Figure 5: INMB histograms comparing 'worst-case + best geo' to worst-case ring vaccination, and 'realistic + best geo' to realistic ring vaccination. Positive values of INMB (in red) indicate that geographic vaccination is more cost effective than ring vaccination, and negative values (in blue) indicate that ring vaccination is more cost effective. In each subplot, the mean INMB for the given scenario is shown, along with the SEM (in brackets), and the percentage of positive and negative INMBs.

Figure 6: ICER planes for a best-case geographically targeted vaccination relative to worst-case and realistic ring vaccination. Outbreak detection time varies across the rows (top: early, middle: medium, bottom: late) and (non-vaccination) response level increases across the columns from left to right. Each point represents a simulation pair. Points in the bottom right corner indicate that geographically targeted vaccination outperforms ring vaccination; points in the top left corner indicate the converse. Red points indicate when the simulated epidemic using geographically targeted vaccination is shorter than the matching simulation using ring vaccination, with blue points indicating the converse. The dashed line indicates the willingness to pay threshold, i.e the VSLY.

In figure 5, we show similar figures comparing 'worst-case + best geo' to worst-case ring vaccination, and 'realistic + best-case geo' to realistic ring vaccination. Again, no strategy wins clearly over the other. For worst-case ring vaccination, geographically targeted vaccination more frequently outperforms ring vaccination, with the effect becoming slightly more pronounced when outbreaks are detected later. However at the realistic response level, ring vaccination outperforms geographically targeted vaccination in the slight majority of simulations.

However, for high transmission level scenarios (figure S13), the best-case geographically targeted vaccination campaign cannot overcome the limitations of worst-case contact tracing and case ascertainment. The daily cap on the number of vaccine doses administered per day also impacts the overall effectiveness of the response, again resulting in long, drawn-out epidemics. Deploying a best-case geographically targeted vaccination campaign when cases are not ascertained efficiently and resources are limited does not infer any additional benefit; in fact, it is less cost-effective than a worst-case ring vaccination campaign.

# 4 Discussion

In this study, we have compared the effectiveness and cost-effectiveness of geographically targeted vaccination to the current gold standard of ring vaccination, assuming a wide range of epidemiological and outbreak response scenarios. For realistic or best-case outbreak responses, we find that on average ring vaccination results in fewer cases, fewer deaths and shorter outbreaks, and is more likely to be cost-effective than geographically targeted vaccination. Under less favourable conditions, however, geographically targeted vaccination marginally outperforms ring vaccination, both in terms of epidemiological and cost-effectiveness metrics. Both of these findings remain consistent even when we consider scenarios in which geographically targeted vaccination is carried out more effectively than ring vaccination. However, it is important to note that both the outbreak response level and outbreak detection time have a much greater impact on health outcomes than vaccination strategy; increasing surveillance levels, case ascertainment and contact follow-up is much more effective at reducing case and death numbers than switching from geographic to ring vaccination or vice versa.

Ring vaccination relies on effective case ascertainment and contact tracing to identify individuals to be vaccinated. Geographically targeted vaccination relies on effective case ascertainment for the first case in a location, but then is less reliant on contact tracing. For ring vaccination, this highlights the importance of finding (through contact tracing) and prioritising protection (through vaccination) of the individuals most vulnerable to EVD infection, i.e. the close contacts of cases, to break transmission chains. For a worst-case response, we assume that only a third of cases are ascertained and vaccination rings are only established around two-thirds of these cases. Therefore, when ring vaccination is employed as part of a worst-case response, many chains of transmission continue unbroken. In contrast, even though geographic vaccination does not necessarily target the most vulnerable contacts, it can at least establish a degree of immunity in the local population during a worst-case response, thus reducing transmission in hot spots. However, improving the efficiency of geographically targeted vaccination alone does not provide meaningful incremental benefits if case ascertainment and contact tracing are still operating at the worst-case level.

In terms of cost-effectiveness, we find that there is a negative correlation between benefits and costs, i.e. if benefits are higher then costs are also lower, and vice versa. This is because effective vaccination strategies curtail both the length of the epidemic and the number of cases and deaths. This results in lower costs as not only are the costs associated with ascertaining, treating and vaccinating cases reduced, but the number of months for which the rapid response team and point of entry screening are needed is also reduced. However, due to a lack of cost data there may be other costs that we have not considered in our analysis. For example, we do not include one-off costs associated with initiating an outbreak response, which are likely to have a disproportionate impact on shorter outbreaks compared to longer outbreaks. Including these costs might change our findings in some scenarios. Our estimates of the cost of safe burials are also preliminary, and result in high costs per safe burial which drive up the costs for simulated outbreaks with high numbers of fatalities. More robust estimates of these costs would help to refine our analyses.

Although we identified some differences in impact and cost-effectiveness between the two vaccination strategies, the mean differences are small and uncertain. On the level of an individual outbreak, we cannot predict which strategy will be most effective. Some of this variability is due to stochastic effects; whilst matched pairs of simulated outbreaks are identical up to outbreak detection and the start of the response, once the different re-

sponses begin and target different individuals for vaccination, the simulated outbreaks start to diverge, sometimes leading to very different results. Part of the divergence is due to limitations in our matching of paired stochastic simulations [53], something which could be improved in future work. However, this is also partly related to differences in vaccination strategies, and therefore an effect we want to capture.

To compare ring and geographically targeted vaccination, we have relied on strict definitions of ring and geographically targeted vaccination in order to emphasise the differences between the strategies. However, challenging field conditions can result in ring vaccination becoming more akin to geographical targeting [54], and behavioural effects can act to make geographically targeted vaccination more similar to ring vaccination campaigns. For example, we have assumed that the doses assigned to geographically targeted vaccination are distributed randomly within the population of the target area. In reality, vaccine acceptance and targetting is likely to be non-random. Some studies on vaccine acceptance have shown that risk-averse individuals, who are less likely to have close contact with infectious individuals, are more likely to voluntarily participate in vaccination programmes [55], which may reduce the likelihood that geographic vaccination reaches vulnerable contacts and thus reduce its effectiveness. However, if high-risk individuals come forward for voluntary vaccination against EVD, geographically targeted vaccination becomes more similar to ring vaccination and could increase the effectiveness of this strategy. When ring vaccination incorporates elements of geographically targeted vaccination, or high-risk contacts self-selectively participate in geographically targeted vaccination campaigns, it is likely that the differences between the strategies will become even narrower. Whilst these effects could be incorporated into transmission models, without detailed data on participation in geographically targeted vaccination campaigns during EVD outbreaks, the impact would more speculative than realistic.

Another key outcome of this work is the number of doses sufficient for 95% of simulated outbreaks, which can be taken as a proxy for necessary stockpile size. Our results show that a stockpile of 700,000 doses would be sufficient to deploy either vaccination strategy in nearly all outbreak scenarios presented here; however, most scenarios we examined require fewer than 100,000 doses per outbreak. The exception is for a worst-case response rolled out in a high transmission scenario, where it would take years and nearly a million doses to achieve control of the outbreak if the response remains at the worst-case level and vaccination administration rates limited. The scenarios we designed and present here were guided by pragmatic experience from the field, but further research is needed to examine and understand the resources and number of doses required to cover these catastrophic scenarios; indeed, in reality the response would likely be stepped up considerably in such a situation. We also note that we only consider one outbreak at a time and that we do not take vaccine dose wastage into account here. In reality, it is possible for multiple outbreaks to occur within a given interval with no opportunity to refresh the stockpile, and that in real-world settings a fraction of doses go to waste. Both of these this factors need to be taken into account when determining necessary stockpile sizes.

Resource limits are a key factor determining the health outcomes and costs associated with an outbreak. In this study, we assumed that the number of vaccine doses administered was capped at 1500 doses per day (irrespective of the vaccination strategy), in line with data recorded during recent EVD outbreaks in DRC. During these outbreaks, vaccination was carried out under the compassionate use protocol which required teams of good clinical practices (GCP) trained vaccinators, detailed registration and consent procedures, and an extended adverse effect follow-up period. Thus, whilst we are confident in the values we derived from the 2018-2020 outbreak data, it is possible that the daily rate of vaccine administration will be higher in the post-licensure period, although we

do not currently have any data to estimate what the increased rate would be. Investigating the impact of this limiting factor on vaccine effectiveness and cost-effectiveness should be explored in the future.

To further understand the most cost-effective vaccination and response strategy, as well as the range of scenarios in which geographical targetting is preferable to ring vaccination, sensitivity analysis should be explored in future, once appropriate data is available, in order to understand which parameters drive cost-effectiveness.

Our results also highlight that outbreak response efficacy has more impact on epidemiological outcomes than the choice of vaccination strategy, and hence assessing the cost-effectiveness of improving outbreak response is an important avenue for future research. However, this requires much more data, particularly on the incremental costs of faster outbreak detection via improved passive surveillance, which is currently lacking.

Overall, ring vaccination has many benefits as it targets those most vulnerable to exposure, but our work demonstrates that for a worst-case response, as may well be the case in remote regions or conflict zones, geographically targeted vaccination can avert more deaths and be less costly. In future, other strategies which incorporate aspects from both ring and geographical vaccination, could also be considered. For example, a combined strategy, including one ring of contacts supplemented by local geographically targeted vaccination, or a hybrid strategy, which favours ring vaccination but employs geographically targeted vaccination when a ring cannot be established, may prove not only more pragmatic but also more cost-effective than any of the two approaches alone. The number of doses deployed per case in the geographic vaccination strategy could also be scaled by local population density to establish higher immunity levels in densely populated areas. However, such a strategy is likely to be resource-intensive, and would require a higher daily vaccination rate than considered in this work (where we used a cap of 1,500 doses a day) to determine whether it can be a more effective alternative to the geographically targeted strategy considered here.

Whilst previous papers have evaluated combined ring and community vaccination [19] or hypothesised the potential benefits of geographically targeted vaccination [56], we believe our study is the first to directly compare effectiveness and cost-effectiveness of reactive ring and geographically targeted vaccination programmes during EVD outbreaks. While ring vaccination is currently recommended by WHO guidelines [57], our results show that there is no systematic difference in outcomes between the two vaccination strategies, and that geographically targeted vaccination may be preferable for a worst-case outbreak response. This has important policy implications as it suggests that vaccination strategy can be chosen pragmatically based on outbreak context, without sacrificing impact. However, perhaps the key finding of this work is that, while vaccination is an important addition to the outbreak response toolbox, it is not a panacea; to curtail EVD outbreaks, we need robust surveillance and traditional outbreak response measures.

**Disclaimer:** K. Hauck and A. Cori received personal fees from Munich Re for work unrelated to this project. A. Bagayoko, A. Costa and P. Lambach work for the World Health Organization (WHO). The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy or views of the WHO.

**Financial support:** GNG, JES, WH, NMF, KH and AC acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking. NMF and KH acknowledge funding by Community Jameel. CABP contributed to this project via cooperative agreement

CDC-RFA-FT-23-0069 from the CDC Center for Forecasting and Outbreak Analytics. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. SR is currently seconded to UKHSA as Chief Data Officer. This work was supported by Gavi, the Vaccine Alliance/ The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy or views of Gavi.

**Code availability:** The code and data required to run and reproduce the analysis presented here is available at $https://github.com/mrc-ide/ebolasim\_public$.

# References

[1] Joel G. Breman et al. "Discovery and Description of Ebola Zaire Virus in 1976 and Relevance to the West African Epidemic During 2013–2016". In: *The Journal of Infectious Diseases* 214.suppl$_3$ (Oct. 2016), S93–S101. ISSN: 0022-1899. DOI: `10.1093/infdis/jiw207`. eprint: `https://academic.oup.com/jid/article-pdf/214/suppl\_3/S93/7935916/jiw207.pdf`. URL: `https://doi.org/10.1093/infdis/jiw207`.

[2] Navin Venkatraman et al. "Vaccines against Ebola virus". In: *Vaccine* 36.36 (2018), pp. 5454–5459. ISSN: 0264-410X. DOI: `https://doi.org/10.1016/j.vaccine.2017.07.054`. URL: `https://www.sciencedirect.com/science/article/pii/S0264410X17309623`.

[3] Henry Kyobe Bosa et al. "The west Africa Ebola virus disease outbreak: 10 years on". In: *The Lancet Global Health* 12.7 (2024). DOI: `10.1016/S2214-109X(24)00129-3`. URL: `https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00129-3/fulltext`.

[4] Ana Maria Henao-Restrepo et al. "Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)" In: *The Lancet* 389.10068 (2017), pp. 505–518. ISSN: 0140-6736. DOI: `https://doi.org/10.1016/S0140-6736(16)32621-6`. URL: `https://www.sciencedirect.com/science/article/pii/S0140673616326216`.

[5] S. Meakin et al. "Effectiveness of rVSV-ZEBOV vaccination during the 2018-2020 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study". In: *The Lancet Infectious Diseases* 24.12 (2024), pp. 1357–1365. DOI: `10.1016/S1473-3099(24)00419-5`.

[6] World Health Organization Strategic Advisory Group of Experts on Immunization. "Meeting of the Strategic Advisory Group of Experts on Immunization, April 2017: conclusions and recommendations". In: *Weekly Epidemiological Record* 92.22 (2017), pp. 301–320. URL: `https://www.who.int/publications/i/item/WER9222`.

[7]     Jayanthi Wolf et al. "Development of Pandemic Vaccines: ERVEBO Case Study". In: *Vaccines* 9.3 (2021). ISSN: 2076-393X. DOI: `10.3390/vaccines9030190`. URL: `https://www.mdpi.com/2076-393X/9/3/190`.

[8]     Team World Health Organization. Ebola Virus Response. *Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response.* Report. 2019. URL: `https://www.who.int/publications/m/item/preliminary-results-on-the-efficacy-of-rvsv-zebov-gp-ebola-vaccine-using-the-strategy-in-the-control-of-an-ebola-outbreak`.

[9]     Moritz U. G. Kraemer et al. "Dynamics of conflict during the Ebola outbreak in the Democratic Republic of the Congo 2018–2019". In: *BMC Medicine* 18.1 (2020), p. 113. ISSN: 1741-7015. DOI: `10.1186/s12916-020-01574-1`. URL: `https://doi.org/10.1186/s12916-020-01574-1`.

[10]    J. D. Kelly et al. "Projections of Ebola outbreak size and duration with and without vaccine use in Equateur, Democratic Republic of Congo, as of May 27, 2018". In: *PLoS ONE* 14.3 (2019), e0213190. DOI: `https://dx.doi.org/10.1371/journal.pone.0213190`. URL: `https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0213190&type=printable`.

[11]    P. Chen, W. Fan, and X. Guo. "A hybrid simulation model to study the impact of combined interventions on Ebola epidemic". In: *PLoS ONE* 16.7 July (2021), e0254044. DOI: `https://dx.doi.org/10.1371/journal.pone.0254044`. URL: `https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0254044&type=printable`.

[12]    Erin N. Bodine, Connor Cook, and Mikayla Shorten. "The potential impact of a prophylactic vaccine for Ebola in Sierra Leone". In: *Mathematical Biosciences & Engineering* 15.2 (2018), pp. 337–359. DOI: `10.3934/mbe.2018015`. URL: `https://www.aimsciences.org/article/doi/10.3934/mbe.2018015`.

[13]    R. Potluri et al. "Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis". In: *PLoS ONE* 15.4 (2020), e0230406. DOI: `https://dx.doi.org/10.1371/journal.pone.0230406`. URL: `https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0230406&type=printable`.

[14]    Z. Xie. "Data fitting and scenario analysis of vaccination in the 2014 Ebola outbreak in Liberia". In: *Osong Public Health and Research Perspectives* 10.3 (2019), pp. 187–201. DOI: `https://dx.doi.org/10.24171/j.phrp.2019.10.3.10`. URL: `http://www.kcdcphrp.org/`.

[15]    Chad Wells et al. "Harnessing Case Isolation and Ring Vaccination to Control Ebola". In: *PLOS Neglected Tropical Diseases* 9.5 (2015), e0003794. URL: `https://doi.org/10.1371/journal.pntd.0003794`.

[16] Chad R. Wells et al. "Ebola vaccination in the Democratic Republic of the Congo". In: *Proceedings of the National Academy of Sciences* 116.20 (2019), pp. 10178–10183. DOI: 10.1073/pnas.1817329116. URL: https://doi.org/10.1073/pnas.1817329116.

[17] Adam Kucharski et al. "Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease". In: *Emerging Infectious Disease journal* 22.1 (2016), p. 105. DOI: 10.3201/eid2201.151410. URL: https://wwwnc.cdc.gov/eid/article/22/1/15-1410_article.

[18] Stefano Merler et al. "Containing Ebola at the Source with Ring Vaccination". In: *PLOS Neglected Tropical Diseases* 10.11 (2016), e0005093. URL: https://doi.org/10.1371/journal.pntd.0005093.

[19] G. Chowell, A. Tariq, and M. Kiskowski. "Vaccination strategies to control Ebola epidemics in the context of variable household inaccessibility levels". In: *PLoS Neglected Tropical Diseases* 13.11 (2019), e0007814. DOI: https://dx.doi.org/10.1371/journal.pntd.0007814. URL: https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0007814&type=printable.

[20] D. Bisanzio et al. "Targeted preventive vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling study". In: *Vaccine* 41.3 (2023), pp. 684–693. DOI: https://dx.doi.org/10.1016/j.vaccine.2022.11.036. URL: https://www.elsevier.com/locate/vaccine.

[21] M. Obeng-Kusi et al. "Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries". In: *Journal of Medical Economics* 24.S1 (2021), pp. 1–13. DOI: https://dx.doi.org/10.1080/13696998.2021.2002092. URL: http://www.tandfonline.com/loi/ijme20.

[22] M. Obeng-Kusi et al. "Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis". In: *Journal of Medical Economics* 25.1 (2022), pp. 894–902. DOI: https://dx.doi.org/10.1080/13696998.2022.2091858. URL: http://www.tandfonline.com/loi/ijme20.

[23] D. Guttieres et al. "Modeling Supply and Demand Dynamics of Vaccines against Epidemic-Prone Pathogens: Case Study of Ebola Virus Disease". In: *Vaccines* 12.1 (2024), p. 24. DOI: https://dx.doi.org/10.3390/vaccines12010024. URL: http://www.mdpi.com/journal/vaccines.

[24] Kyra H. Grantz et al. "Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea". In: *Vaccine* 37.48 (2019), pp. 7165–7170. ISSN: 0264-410X. DOI: https://doi.org/10.1016/j.vaccine.2019.09.094. URL: https://www.sciencedirect.com/science/article/pii/S0264410X19313362.

[25] Neil M. Ferguson et al. "Strategies for mitigating an influenza pandemic". In: *Nature* 442.7101 (2006), pp. 448–452. ISSN: 1476-4687. DOI: 10.1038/nature04795. URL: `https://doi.org/10.1038/nature04795`.

[26] Amy Rose et al. *LandScan Global 2018*. Dataset. 2019. DOI: `https://doi.org/10.48690/1524213`. URL: `landscan.ornl.gov`.

[27] Database of Global Administrative Boundaries (GADM). *GADM Version 3.6*. Dataset. 2018. URL: `https://gadm.org/`.

[28] Ministère du Plan et Suivi de la Mise en œuvre de la Révolution de la Modernité - MPSMRM/Congo, Ministère de la Santé Publique - MSP/Congo, and ICF International. *République Démocratique du Congo Enquête Démographique et de Santé (EDS-RDC) 2013-2014*. Report. For assistance using downloaded citations from The DHS Program, please visit http://dhsprogram.com/publications/Citing-DHS-Publications.cfm Pour tous renseignements concernant l'EDS-RDC II, contacter le Ministère du Plan et SMRM, 4155, Rue des Coteaux, Quartier Petit Pont, Kinshasa/Gombe, BP 9378 Kin 1, Kinshasa, E-mail: miniplan@gmail.com. Pour obtenir des informations sur le programme MEASURE DHS, contactez ICF International, 530, Gaither Road, Suite 500, Rockville, MD 20850, USA ; Téléphone: 301-407-6500, Fax: 301-407-6501, E-mail: info@DHSprogram.com, Internet: www.DHSprogram.com. MPSMRM, MSP, and ICF International, 2014. URL: `http://dhsprogram.com/pubs/pdf/FR300/FR300.pdf`.

[29] null null. "Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward Projections". In: *New England Journal of Medicine* 371.16 (2014), pp. 1481–1495. DOI: 10.1056/NEJMoa1411100. eprint: `https://www.nejm.org/doi/pdf/10.1056/NEJMoa1411100`. URL: `https://www.nejm.org/doi/full/10.1056/NEJMoa1411100`.

[30] Team International Ebola Response et al. "Exposure Patterns Driving Ebola Transmission in West Africa: A Retrospective Observational Study". In: *PLOS Medicine* 13.11 (2016), e1002170. DOI: 10.1371/journal.pmed.1002170. URL: `https://doi.org/10.1371/journal.pmed.1002170`.

[31] Placide Mbala-Kingebeni et al. "2018 Ebola virus disease outbreak in Equateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation". In: *The Lancet Infectious Diseases* 19.6 (2019). doi: 10.1016/S1473-3099(19)30124-0, pp. 641–647. ISSN: 1473-3099. DOI: 10.1016/S1473-3099(19)30124-0. URL: `https://doi.org/10.1016/S1473-3099(19)30124-0`.

[32] Ali S. Khan et al. "The Reemergence of Ebola Hemorrhagic Fever, Democratic Republic of the Congo, 1995". In: *The Journal of Infectious Diseases* 179.Supplement_1 (1999), S76–S86. ISSN: 0022-1899. DOI: 10.1086/514306. URL: `https://doi.org/10.1086/514306`.

[33] "Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward Projections". In: *New England Journal of Medicine* 371.16 (2014). doi: 10.1056/NEJMoa1411100, pp. 1481–1495. ISSN: 0028-4793. DOI: 10.1056/NEJMoa1411100. URL: https://doi.org/10.1056/NEJMoa1411100.

[34] A. Warsame et al. "Performance of a safe and dignified burial intervention during an Ebola epidemic in the eastern Democratic Republic of the Congo, 2018–2019". In: *BMC Medicine* 21.1 (2023), p. 484. ISSN: 1741-7015. DOI: 10.1186/s12916-023-03194-x.

[35] Oly Ilunga Kalenga et al. "The Ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018–2019". In: *New England Journal of Medicine* 381.4 (2019), pp. 373–383. DOI: 10.1056/NEJMsr1904253. URL: https://www.nejm.org/doi/full/10.1056/NEJMsr1904253.

[36] Africa World Health Organization. Regional Office for. *Ebola Virus Disease Democratic Republic of Congo: External Situation Report 27 / 2019*. Report. World Health Organization. Regional Office for Africa, 2019. URL: https://apps.who.int/iris/handle/10665/279992.

[37] Africa World Health Organization. Regional Office for. *Ebola Virus Disease Democratic Republic of Congo: External Situation Report 01 (2018)*. Report. World Health Organization. Regional Office for Africa, 2018. URL: https://apps.who.int/iris/handle/10665/272509.

[38] Africa World Health Organization. Regional Office for. *Ebola Virus Disease Democratic Republic of Congo: External Situation Report 38 / 2019*. Report. World Health Organization. Regional Office for Africa, 2019. URL: https://iris.who.int/handle/10665/312080.

[39] World Health Organization. Emergency Preparedness Team. *Implementation and management of contact tracing for Ebola virus disease*. Report. World Health Organization, 2020. URL: https://www.who.int/publications/i/item/WHO-EVD-Guidance-Contact-15.1.

[40] Merck. *U.S. FDA Approves Merck's ERVEBO (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older*. News. 2023. URL: https://www.merck.com/news/u-s-fda-approves-mercks-ervebo-ebola-zaire-vaccine-live-for-use-in-children-12-months-of-age-and-older/.

[41] Maria D. Van Kerkhove et al. "A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making". In: *Scientific Data* 2.1 (2015), p. 150019. ISSN: 2052-4463. DOI: 10.1038/sdata.2015.19. URL: https://doi.org/10.1038/sdata.2015.19.

[42] H. Juliette T. Unwin et al. "Using next generation matrices to estimate the proportion of infections that are not detected in an outbreak". In: *Epidemics* 41 (2022), p. 100637. ISSN: 1755-4365. DOI: https://doi.org/10.1016/j.epidem.2022.100637. URL: https://www.sciencedirect.com/science/article/pii/S1755436522000779.

[43] Mikiko Senga et al. "Contact tracing performance during the Ebola virus disease outbreak in Kenema district, Sierra Leone". In: *Philosophical Transactions of the Royal Society B: Biological Sciences* 372.1721 (2017), p. 20160300. DOI: `doi:10.1098/rstb.2016.0300`. URL: `https://royalsocietypublishing.org/doi/abs/10.1098/rstb.2016.0300`.

[44] The MathWorks Inc. *MATLAB version: 9.13.0 (R2022b)*. Natick, Massachusetts, United States, 2022. URL: `https://www.mathworks.com`.

[45] Africa World Health Organization. Regional Office for. *Democratic Republic of the Congo*. Web Page. 2023. URL: `https://data.who.int/countries/180`.

[46] A. Basu and T.G. Ganiats. "Discounting in Cost-Effectiveness Analysis". In: 2nd Edition. Oxford University Press, 2017. Chap. 10.

[47] Zeng Wu et al. "The cost of public health interventions to respond to the 10th Ebola outbreak in the Democratic Republic of the Congo". In: *BMJ Global Health* 8.10 (2023), e012660. DOI: `10.1136/bmjgh-2023-012660`. URL: `http://gh.bmj.com/content/8/10/e012660.abstract`.

[48] Africa World Health Organization. Regional Office for. *Ebola Virus Disease Democratic Republic of Congo: External Situation Report 85 / 2020*. Report. World Health Organization. Regional Office for Africa, 2020. URL: `https://iris.who.int/handle/10665/331537`.

[49] Africa World Health Organization. Regional Office for. *Ebola Virus Disease Democratic Republic of Congo: External Situation Report 88 / 2020*. Report. World Health Organization. Regional Office for Africa, 2020. URL: `https://iris.who.int/handle/10665/331759`.

[50] World Health Organization. Emergency Preparedness Team. *WHO recommended criteria for declaring the end of the Ebola virus disease outbreak*. Report. World Health Organization, 2020. URL: `https://www.who.int/publications/m/item/who-recommended-criteria-for-declaring-the-end-of-the-ebola-virus-disease-outbreak`.

[51] Bryan N. Patenaude et al. "The Value of a Statistical Life-Year in Sub-Saharan Africa: Evidence From a Large Population-Based Survey in Tanzania". In: *Value in Health Regional Issues* 19 (2019), pp. 151–156. ISSN: 2212-1099. DOI: `https://doi.org/10.1016/j.vhri.2019.07.009`. URL: `https://www.sciencedirect.com/science/article/pii/S2212109919300950`.

[52] World Bank Group. *World Bank Open Data*. Dataset. 2025. URL: `https://data.worldbank.org`.

[53] Joshua Kaminsky et al. "Perfect counterfactuals for epidemic simulations". In: *Philosophical Transactions of the Royal Society B: Biological Sciences* 374.1776 (July 2019), p. 20180279. ISSN: 0962-8436, 1471-2970. DOI: `10.1098/rstb.2018.0279`. URL: `https://royalsocietypublishing.org/doi/10.1098/rstb.2018.0279` (visited on 04/15/2025).

[54]   Team World Health Organization. Ebola Virus Response. *Second Ebola vaccine to complement "ring vaccination" given green light in DRC*. Web Page. 2019. URL: `https://www.who.int/news/item/23-09-2019-second-ebola-vaccine-to-complement-ring-vaccination-given-green-light-in-drc`.

[55]   Anthony Lepinteur et al. "Risk aversion and COVID-19 vaccine hesitancy". In: *Health Economics* 32.8 (2023), pp. 1659–1669. DOI: `https://doi.org/10.1002/hec.4693`. eprint: `https://onlinelibrary.wiley.com/doi/pdf/10.1002/hec.4693`. URL: `https://onlinelibrary.wiley.com/doi/abs/10.1002/hec.4693`.

[56]   Jenny A. Walldorf et al. "Considerations for use of Ebola vaccine during an emergency response". In: *Vaccine* 37.48 (2019), pp. 7190–7200. ISSN: 0264-410X. DOI: `https://doi.org/10.1016/j.vaccine.2017.08.058`. URL: `https://www.sciencedirect.com/science/article/pii/S0264410X17311568`.

[57]   World Health Organization Strategic Advisory Group of Experts on Immunization. *Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization on Ebola vaccination, May 2024: conclusions and recommendations*. Report. 2024. URL: `https://www.who.int/publications/i/item/WER-9927-355-362`.